financially, political stability and good governance are often
important factors in attracting foreign aid [16]. In this regard,
good country-level governance was previously shown to have a
considerable impact on investments in developing countries made
by for-profit healthcare service providers and large multinational
pharmaceutical and biotechnology corporations [17].
In addition to funding, the introduction of new vaccines
requires adequate infrastructure elements such as sufficient cold
chain capacity, ability to reach remote locations, safe disposal of
needles and syringes, as well as sufficient numbers of adequately
trained personnel [18]. Lack or scarcity of these elements
constitute significant barriers to the adoption of new vaccines
[18]. Country-level governance may have a crucial effect on both
the initiation and mobilization of these important elements of
vaccine programs.
Combining Governance Indicators into a single index has the
advantage of providing one measure of governance that will take
into account all the indicators. Although overall, we found a
correlation between the various indicators of governance, some
countries received substantially different scores for different
Governance Indicators. Thus, a combined Governance score
which takes into account all the components of governance,
without the need to evaluate each one of them separately, provides
a user-friendly measure of governance.
Our results indicate that a scoring system that takes into account
all Governance Indicators (Figure 3) may constitute an effective
quantitative method to predict the ability of poor nations in Africa
to introduce new vaccines. There is a great need for quality
quantitative tools to support decision making in healthcare
philanthropy, and efforts to develop such tools are thus far at
their infancy (http://aspe.hhs.gov/hsp/09/philnpart/chapter5.
shtml). During its first phase of operations, GAVI strongly
encouraged nations to apply for new vaccines. GAVI has been
using a rigorous approach to evaluating, awarding and monitoring
its grants, while attempting to consider individual countries’
priorities, and promoting planning and country ownership.
However, an independent evaluation of the first phase of GAVI
found that it did not use a formal framework in directing its decision
making process regarding approval of funding (www.gavialliance.
org/resources/5._GAVI_Phase_1_Evaluation_Executive_Summary.
pdf). Thus, the association of new vaccines introduction with high
country-level governance scores reflects a phenomenon that is
independent of a specific framework. Our findings could provide a
basis for designing a framework and/or criteria that will guide the
evaluation process and the support required for introducing new
vaccines into nations with different levels of governance scores.
Overall, our findings suggest that for a new vaccine programs to
succeed, special considerations and criteria should be applied to
different countries. Countries with higher governance scores can
be expected to respond faster to GAVI and other international
vaccine initiatives. Although concerns regarding the financial
sustainability of these immunization programs are expected, it is
reasonable to assume that if financial resources are provided to
nations with higher governance scores, vaccination programs that
are in place will continue. However, in the absence of good
country-level governance, such as in the case of country group III,
the ability to respond to international vaccine initiatives will likely
be slower and the optimal use of financial assistance may be at risk.
Although the countries that pioneered the Hib program in sub-
Saharan Africa had overall good governance scores, a real
question remains whether, absent some significant price conces-
sion, even they can sustain this expensive vaccine once GAVI
funding ends. This question has become more relevant since
GAVI has continued to approve Hib vaccine funding to additional
African countries (www.gavialliance.org/media_centre/press_
releases/2007_11_29_en_pr_hib_boost.php). While some of these
newly approved countries had already introduced the HepB
vaccine beforehand, and they belong to an overall more
governmentally resourceful group of countries, most of them had
not used Hib or HepB vaccine before, and they belong to an
overall weaker group of countries with less effective governmental
systems.
GAVI has already begun modifying its criteria for financial
support for fragile countries. These include providing funds to
strengthen health systems (www.gavialliance.org/performance/
evaluation/index.php) and requiring lower co-pays for vaccines
(http://hibaction.org/resources/hibfocus/061117_alert/) [14]. The
need for additional support and different rules of engagement with
those nations (many of which are post-conflict) have been discussed
during GAVI’s meetings (www.gavialliance.org/resources/19brd_
FragileStates.pdf). Analysis of the second phase of GAVI’s funding
(from 2007 to 2010) will be required to evaluate the success of the
new changes in affecting new vaccine introduction. Ultimately,
established criteria, such as those used by the Center for Global
Development to assess the long-term success of global health
initiatives, namely: scale, importance, impact, duration and cost-
effectiveness [12], will probably be most suitable for this purpose.
The issues discussed in this paper are of paramount importance
for the continued introduction of new vaccines into developing
countries as well as maintaining and sustaining immunization
programs. In this regard, additional new licensed vaccines such as
Pneumococcal, Rotavirus, and Human papillomavirus vaccines are
planned to follow HepB and Hib vaccines (www.gavialliance.org/
vision/policies/new_vaccines/adips/index.php; www.gavialliance.
org/resources/FS_HPV_EN.pdf). If these vaccines are successfully
introduced into poor nations, they will likely facilitate the
introduction of novel vaccines to prevent tuberculosis, malaria
and HIV/AIDS when available.
Acknowledgments
We are grateful to Dr. D. Modan-Moses for critical reading of the
manuscript and helpful suggestions.
Author Contributions
Conceived and designed the experiments: AGF VGR DWB. Performed
the experiments: AGF DWB. Analyzed the data: AGF DWB. Wrote the
paper: AGF MLC KAN RFP IRS KS. Data acquisition, data
interpretation: AGF. Data acquisition, drafting the article, final approval
of submitted version: MLC KAN RFP IRS KS. Critical revision of the
article for important intellectual content, final approval of the submitted
version: VGR DWB.
References
1. Murray CJ, Laakso T, Shibuya K, Hill K, Lopez AD (2007) Can we achieve
Millennium Development Goal 4? New analysis of country trends and forecasts
of under-5 mortality to 2015. Lancet 370: 1040–1054.
2. Anonymous (2006) Vaccine preventable deaths and the Global Immunization
Vision and Strategy, 2006–2015. MMWR 55: 511–515.
3. Mathers CD, Lopez AD, Murray CJL (2006) The burden of disease and
mortality by condition: Data, methods, and results by 2001. In: Lopez AD,
Mathers CD, Ezzati M, Jamison DT, Mu rray CJL, eds. Glob al burden of
disease and risk factors. New York: Oxford University Press. pp 45–
240.
4. Aylward RB, Birmingham M, Lloyd J, Eggers R, Bilous J, et al. (2010) Reaching
every child: Achieving equity in global immunization. In: Levine MM, et al. (2010)
New Generation Vaccines, 4th edn. New York: Informa Healthcare. pp 91–
100.
New Vaccines for Poor Nations
PLoS ONE | www.plosone.org 8 November 2010 | Volume 5 | Issue 11 | e13802